BroadOak Logo


We bring the power of our platform, connections and experience to every investment and enjoy backing teams and businesses that are generally misunderstood or overlooked by the broader market.

Our Investment Approach

BroadOak Asset Management was founded to address the capital needs of underserved, growth-stage life sciences companies. Many next-generation technologies start their development within these companies, but founders often struggle to find the right partner for the capital and support needed to become successful. Most capital providers avoid our markets due to a combination of the perceived complexity and risk of life sciences as well as ever-increasing minimum investment sizes.

We work with commercial-stage companies that have bright futures. Our broad investment mandate means our deal structures and investment sizes are flexible.

Investment Statistics

Companies Invested




Total Platform Capital Invested




Special Purpose Vehicles


Investment Criteria

Since our first investment in 2010, we have invested in more than 50 companies. BroadOak has stayed true to its goal of providing resources to traditionally overlooked companies. We are often the first institutional investor in our portfolio companies.

  • Industry: Life sciences tools, services, and biopharma services
  • Stage: Commercial stage companies with proven market need for the company’s products or services
  • Financial profile: We invest in commercial-stage companies from initial revenue through profitability.

What Makes Us Unique

Flexible Structure

Long Term Investment Horizon

Deep Industry Expertise

Merchant Banking Model

No Minimum Investment

Operational Experience

Fund V

We are actively investing out of our fifth fund, leveraging knowledge and expertise developed over the firm’s 15-year history. Fund V is our largest fund yet.

Investment Criteria

Debt & Equity



Industry Executives are Fund V LPs


Fund IV Investors Invested in Fund V


Launched in


BioTools Venture Fund​

Launched in collaboration with DeciBio in October 2022, the BroadOak BioTools Venture Fund provides early stage growth capital to promising young companies. With a world-class ecosystem of investors, strategics, and mentors, BroadOak BioTools Venture Fund offers pre-commercial companies tremendous value to accelerate their growth.

Growth Stage: 6-9 months pre-commercialization

Industry Sector: biotools with a focus on CGT

Launched in 2022

Ecosystem of investors, strategics, and mentors


Our partnership with BroadOak extends far beyond a capital investment. Their advice and industry connections have been valuable assets in our growth strategy.

Rick Gordon
CEO | Halo Labs

BroadOak Logo Only

Our Portfolio

BroadOak has invested in more than 65 outstanding companies. Get to know our portfolio companies.